Clinical outcomes of liposomal irinotecan plus fluorouracil/leucovorin for metastatic pancreatic adenocarcinoma in patients previously treated with conventional irinotecan-containing chemotherapy

INTRODUCTION: Liposomal irinotecan (nal-IRI) plus fluorouracil/leucovorin (5-FU/LV) has shown clinical benefit in patients with metastatic pancreatic adenocarcinoma (mPAC) who progressed on gemcitabine-based chemotherapy. However, its role in patients with mPAC previously treated with conventional i...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Ther Adv Med Oncol
Main Authors: Bang, Kyunghye, Cheon, Jaekyung, Jeong, Jae Ho, Im, Hyeon-Su, Kim, Kyu-pyo, Ryoo, Baek-Yeol, Yoo, Changhoon
פורמט: Artigo
שפה:Inglês
יצא לאור: SAGE Publications 2021
נושאים:
Original Research
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC7983461/
https://ncbi.nlm.nih.gov/pubmed/33796153
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/17588359211003053
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים